Although we have few HER2+ breast cancers in our collection, we have models from individuals with metastatic breast cancer who had HER2+ primary tumors but whose tumors lacked HER2 amplification following progression after HER2-targeted therapy (Supplementary Table 1). This evidence concerns the gene ERBB2 and breast carcinoma.